Brief: Lantern Pharma Inc - Establishes Ai Center Of Excellence In Bengaluru
12/01/2026 14:08
Jan 12 (Reuters) - Lantern Pharma Inc LTRN.O: LANTERN PHARMA INC - ESTABLISHES AI CENTER OF EXCELLENCE IN BENGALURU LANTERN PHARMA INC - HIRING INITIATED, EXPANSION EXPECTED TO BE CASH FLOW NEUTRAL LANTERN PHARMA INC - PHASE 1 FOCUSES ON AI-DRIVEN CANCER DRUG DEVELOPMENT LANTERN PHARMA INC - PHASE 2 FOCUSES ON MULTI-DISEASE EXPANSION AND REVENUE ACCELERATION Source text: ID:nBw1lXc0xa Further company coverage: LTRN.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lantern Pharma
See all newsBrief: Lantern Pharma Receives Taiwan Approvals To Open Next Stage Of Phase 2 Harmonic Trial Of Lp-300 In Never-Smoker, Egfr-Mutant Nsclc
Brief: Lantern Pharma Reports Second Quarter 2026 Financial Results And Provides Business Update
Lantern Pharma Inc reports results for the quarter ended June 30 - Earnings Summary
Lantern Pharma Q2 operating loss widens on warrant expenses tied to higher stock price
Lantern Pharma Inc expected to post a loss of 38 cents a share - Earnings Preview